http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2540744-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d5476cb5e82e42115d0e9188a17c843
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
filingDate 2010-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a5cdef3f34491667364654047aa6683
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90bb9878c9b058c70d786eec71219866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98ed7aab6ad14a5bcf8b34856d89b14f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9c50224a0feda008fe16beead33d808
publicationDate 2013-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2540744-A1
titleOfInvention Fully human monoclonal antibody to vegf, preparation method and use thereof
abstract The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.
priorityDate 2010-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008133706-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009060198-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009073160-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005054273-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCC0K3N4
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ00731
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCF6QDM7
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA0A3Q2TVI4
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID159333
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP67860
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP26617
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7422
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403802
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID22339
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83906
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP50412
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP49151
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419594614
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP16612
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ99PS1
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID558154
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9MYV3
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID30682
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP67965
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID83785
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCC0K3N5
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15691
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281572
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCH0ZCS4
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15692
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9GKR0
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP67964
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID395909

Total number of triples: 58.